A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects

Trial Profile

A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects

Suspended
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs ASP 7713 (Primary)
  • Indications Bladder dysfunction
  • Focus Adverse reactions
  • Sponsors Astellas Pharma BV
  • Most Recent Events

    • 24 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
    • 24 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
    • 24 Oct 2017 Status changed from recruiting to suspended because of management decision related to the PK profile of the compound and the need for interim evaluation of the development program of the compound.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top